- Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions - https://eyedocnews.com -

Bausch + Lomb Acquiring ISTA Pharmaceuticals

Posted By Dr. Ari Weitzner On April 9, 2012 @ 2:41 pm In Dry Eye,Glaucoma,Industry News | Comments Disabled

In late March, Bausch + Lomb and ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) announced that they have signed a definitive agreement under which Bausch + Lomb will acquire ISTA for $9.10 per share in cash, or a total of approximately $500 million.

Executives anticipate that Bausch + Lomb will help ISTA strengthen its pipeline and market its products by combining ISTA’s portfolio of non-steroidal, anti-inflammatory, allergy, and glaucoma dropsĀ (such as XIBROM [1] and Bromday [2]) to Bausch + Lomb’s portfolio of existing Rx ophthalmology and OTC eye health products. ISTA’s pipeline includes candidates in various stages of development to treat various ocular conditions including inflammation and pain, while Bausch + Lomb’s pipeline of pharmaceutical innovations include the first of a new class of ocular anti-inflammatory agents to come along in decades, and a promising approach to reducing intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension.

Click here [3] for the full press release.


Article printed from Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions: https://eyedocnews.com

URL to article: https://eyedocnews.com/006625-bausch-lomb-acquiring-ista-pharmaceuticals/

URLs in this post:

[1] XIBROM: http://eyedocnews.com/002073-ista-pharmaceuticals-announces-positive-results-for-xibrom/

[2] Bromday: http://eyedocnews.com/003572-once-daily-bromday-drops-from-ista-approved-for-cataract-patients/

[3] Click here: http://phx.corporate-ir.net/phoenix.zhtml?c=121179&p=irol-newsArticle&ID=1676774&highlight=

Copyright © 2008 Eye Doc Talk. All rights reserved.